Sofinnova Partners closes €650M ($750M) Capital XI, greatly exceeding initial target to back early-stage healthcare deals
- Total capital raised across Sofinnova’s platform reaches €1.5Bn over the past year
- Sofinnova Capital XI is actively investing in early-stage biotech and medtech companies across Europe and the US
PARIS, France – November 17, 2025 – Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the close of its latest flagship fund, Sofinnova Capital XI, at €650 million ($750 million), greatly exceeding its initial target.
